RBC Capital Reiterates Outperform on Caribou Biosciences, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Caribou Biosciences (NASDAQ:CRBU) and maintained a $19 price target.

March 12, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating and a $19 price target on Caribou Biosciences.
The reiteration of an Outperform rating and maintenance of a $19 price target by a reputable analyst like Luca Issi from RBC Capital could instill confidence among investors and potentially lead to a positive short-term impact on CRBU's stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100